Skip to main content

Advertisement

Figure 5 | AIDS Research and Therapy

Figure 5

From: The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients

Figure 5

Viral Replication and Cell Viability assays in the presence of the cdk4/6/Cyclin D inhibitor Fascaplysin. A) J1.1 and U1 latently infected HIV-1 cell lines were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Cell culture supernatants were collected at 48 hours post treatment and assayed for reverse transcriptase (RT) activity measured in cpm. DMSO treatment served as a negative control. B) Jurkat, J1.1, U937, and U1 cell lines were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Fourty-eight hours post treatment, the cells were measured for viability with MTT reagent. DMSO treatment served as a negative control. C) Jurkat uninfected T cells were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Cells were collected at 48 hours post treatment and western blotted for the presence of Rb and Actin. DMSO treatment served as a negative control.

Back to article page